AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Markets will remain closed on 2nd April, 2020 on account of Ram Navami.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6%
Fri, 15 Nov

AUROBINDO PHARMA has announced its results for the quarter ended September 2019. Here is a detailed performance review of the same:

AUROBINDO PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Sep-18*
3
Jun-19*
3
Sep-19*
QoQ ChangeYoY Change
Net SalesRs m47,51454,44656,0052.9%17.9%
Other incomeRs m26315820630.7%-21.5%
TurnoverRs m47,77754,60456,2112.9%17.7%
ExpensesRs m37,65142,98244,6033.8%18.5%
Gross profitRs m9,59411,33711,275-0.6%17.5%
DepreciationRs m1,6372,4092,4331.0%48.6%
InterestRs m354499409-17.9%15.7%
Profit before taxRs m7,8668,5878,6380.6%9.8%
TaxRs m1,7542,2782,244-1.5%27.9%
Profit after taxRs m6,1126,3106,3951.3%4.6%
Gross profit margin%20.220.820.1
Effective tax rate%22.326.526.0
Net profit margin%12.811.611.4
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 17.9% on a year-on-year (YoY) basis. The expenses were up by 18.5% YoY during the same period.
  • The company's operating profit increased by 17.5% YoY during the quarter. Consequently, operating profit margins remained same and stood at 20.1% in 2QFY20.
  • Depreciation charges increased by 48.6% and finance costs increased by 15.7% YoY, respectively.
  • Other income declined by 21.5% YoY during the quarter.
  • Net profit for the quarter increased by 4.6% YoY. Net profit margins during the quarter declined from 12.8% in 2QFY19 to 11.4% in 2QFY20.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 2.9% on a quarter-on-quarter (QoQ) basis. The expenses were up by 3.8% QoQ during the same period.
  • The company's operating profit declined by 0.6% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 20.1% in 2QFY20 as against 20.8% in 1QFY19.
  • Net profit for the quarter increased by 1.3% QoQ, while net profit margins declined from 11.6% in 1QFY19 to 11.4% in 2QFY20.

To see how AUROBINDO PHARMA has performed over the last eight quarters,please visit here.

Now or Never: Access Details of the No. 1 Small Cap Stock of 2020
AUROBINDO PHARMA Share Price Performance

Over the last one year,AUROBINDO PHARMA share price has moved down from Rs 780.2 to Rs 401.7, registering a Loss of Rs 378.5 or around 48.5%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 12,958.4 (up 0.3%). Over the last one year it has moved down from 14,276.6 to 12,958.4, a gain of 1,318 points (down 9.2%).

Overall, the S&P BSE SENSEX is up 15.2% over the year.

Current Valuations

At the current price of Rs 401.7, the price to earnings (P/E) ratio of AUROBINDO PHARMA stands at 9.2 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 1.7 times.

Equitymaster requests your view! Post a comment on "AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6%". Click here!

  

Related Views on News

AUROBINDO PHARMA Plunges by 5%; BSE HEALTHCARE Index Down 1.5% (Market Updates)

Apr 1, 2020 | Updated on Apr 1, 2020

AUROBINDO PHARMA share price has plunged by 5% and its current market price is Rs 435. The BSE HEALTHCARE is down by 1.5%. The top gainers in the BSE HEALTHCARE Index are JUBILANT LIFE SCIENCES (up 5.6%) and SHILPA MEDICARE (up 5.0%). The top losers is AUROBINDO PHARMA (down 5.3%).

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Apr 1, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS